

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	213	66	37	19	3	1	09/19/2014	230	106
						213	66	37	19	3	1			
		2	Y 2	Continuous Dosing	280	86	29	13	5	2	0	09/19/2014		
				3 Intermittent Dosing		84	23	13	6	5	1			
						170	52	26	11	7	1			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	7	6	4	2	0	0	02/06/2017	75	39
						7	6	4	2	0	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	2	2	2	1	0	0	10/23/2017		84
				2 Nivolumab + Ipilimumab		6	6	5	2	0	0			
						8	8	7	3	0	0			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		26	11	4	2	1	0	11/03/2015	346	146
						26	11	4	2	1	0			
		2	E	Total Registrations		7	4	2	2	0	0	11/03/2015		
						7	4	2	2	0	0			
	EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	14	0	0	0	0	03/25/2016	303	120
						36	14	0	0	0	0			

26-APR-2018 6:10
MELAN Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1607 MELAN, Adv, T-VEC, MK-3475	1 Registration	02-Oct-17